GlyPort Inc. uses proprietary and patented drug delivery technology, licensed from UCSD, to develop novel drug delivery systems that transform existing drugs in the market into more efficient and effective therapeutics with lower toxic side effects. The first anticancer drug candidate based on the firm's technology has been successfully developed and is in the process of biological testing. Our technology will change the pharmaceutical landscape and expand its boundaries
